What are acquired IPR&D and milestones expenses?

Acquired IPR&D and milestones expenses typically arise from collaborations, licensing agreements, and other asset acquisitions. They represent costs incurred for research and development activities that AbbVie has acquired or for reaching specific development milestones with external partners. These expenses are often unpredictable in their occurrence and timing.

How will this impact AbbVie's profitability?

These expenses are expected to have a $0.04 negative impact on both GAAP and non-GAAP diluted earnings per share for the third quarter of 2023 on a pre-tax basis. AbbVie has incorporated this into its updated earnings guidance for both the quarter and the full year.

Why wasn't this expense previously forecasted?

AbbVie does not forecast acquired IPR&D and milestones expenses because the future occurrence and timing of these transactions are uncertain. The company only provided guidance for these expenses incurred up to the second quarter of 2023.

Are the reported numbers final?

No, the results for the quarter ended September 30, 2023, are preliminary and have not been finalized. They are subject to the company's financial statement closing procedures, and there is no guarantee that the final results will not differ from these estimates.

ABBV 8-K: Earnings & Results

Summary

AbbVie Inc. (ABBV) has filed an 8-K report providing preliminary financial insights for the third quarter of 2023, ending September 30, 2023. The company expects acquired In-Process Research & Development (IPR&D) and milestones expenses to negatively impact both GAAP and non-GAAP diluted earnings per share by $0.04 on a pre-tax basis. This expense, totaling $66 million, was not previously forecasted due to its uncertain nature. While these are preliminary estimates and final results may vary, AbbVie has updated its full-year and third-quarter adjusted diluted earnings per share guidance to reflect this event. The updated full-year 2023 adjusted diluted EPS guidance is now projected to be in the range of $10.86 to $11.06, and the third-quarter 2023 adjusted diluted EPS guidance is revised to $2.76 to $2.86. Investors should note that the information furnished in this report is not considered 'Filed' and therefore does not carry the same liability as traditional SEC filings, but it provides important context for the company's current financial outlook.

Key Highlights

1AbbVie expects $66 million in acquired IPR&D and milestones expenses in Q3 2023.
2These expenses are estimated to reduce both GAAP and non-GAAP diluted EPS by $0.04 in Q3 2023.
3Acquired IPR&D and milestones expenses are inherently unpredictable and were not previously forecasted beyond Q2 2023.
4Full-year 2023 adjusted diluted EPS guidance is updated to a range of $10.86 - $11.06.
5Third-quarter 2023 adjusted diluted EPS guidance is updated to a range of $2.76 - $2.86.
6The information provided is furnished and not 'Filed' under Section 18 of the Exchange Act, meaning it doesn't carry the same legal liabilities.

AbbVie Inc. 8-K Report, Financial Results (Oct 4, 2023)

Summary

Key Highlights

Frequently Asked Questions